bit bio has unveiled a new executive team following its rebranding from Elpis Biomed in October.
The biotech, which specialises in coding and reprogramming stem cells, is now headed by chief executive Mark Kotter, a stem cell biologist and neurosurgeon at the University of Cambridge, while Florian Schuster, the former finance boss of Tessa Therapeutics, is taking up the positions of chief financial and chief operations officer.
The firm’s chief business officer, meanwhile, is Paul Morrill, the co-founder of gene editing firm Horizon Discovery Group PLC (LON:HZD), with immune-oncology clinician Ramy Ibrahim and stem cell reprogramming specialist Marius Wernig serving as scientific advisors.
Ibrahim and Wernig join chief scientific adviser Roger Pedersen, a thought leader in stem cell biology and a co-founder of the Cambridge Stem Cell Institute.
The company is aiming to commercialise Opti-OX, a technology to efficiently and consistently reprogram human stem cells for research, drug discovery and cell therapy.